JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265562

Human ITFG1 (CDA08) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ITFG1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human ITFG1 (CDA08) knockout HeLa cell line (AB265562)
  • Sanger seq

Unknown

Sanger Sequencing - Human ITFG1 (CDA08) knockout HeLa cell line (AB265562)

Homozygous : Insertion of the selection cassette in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265562-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265562-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265562 Human ITFG1 (CDA08) knockout HeLa cell line", "number":"AB265562-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265562-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265562-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265562 Human ITFG1 (CDA08) knockout HeLa cell line", "number":"AB265562-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265562-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265562 Human ITFG1 (CDA08) knockout HeLa cell line", "number":"AB265562-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265562-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265562 Human ITFG1 (CDA08) knockout HeLa cell line", "number":"AB265562-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ITFG1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CDA08 also known as cytidine deaminase weighs approximately 16 kDa and is expressed mainly in the spleen liver and bone marrow. This enzyme catalyzes the deamination of cytidine transforming cytidine into uridine and plays a role in nucleotide metabolism. By conducting this reaction CDA08 regulates cytidine and deoxycytidine levels impacting DNA and RNA synthesis.
Biological function summary

The enzyme CDA08 modulates cell proliferation and apoptosis through its regulation of nucleotide pools. It is not part of any known larger protein complex standing as a singular enzyme in its function. CDA08 activity influences the balance between pyrimidine metabolites impacting cellular functions such as DNA repair and replication.

Pathways

Scientists have linked CDA08 to the pyrimidine metabolism and nucleic acid synthesis pathways. Its activity integrates with key enzymes in these processes maintaining cellular nucleotide homeostasis. Additionally proteins like ribonucleotide reductase interact functionally with CDA08 showing a coordinated regulation of deoxycytidine triphosphate levels essential for DNA synthesis.

Researchers have connected CDA08 with acute myeloid leukemia and certain lymphomas. Alterations in CDA08 expression or activity can affect chemotherapeutic drug metabolism influencing treatment outcomes. Furthermore proteins such as deoxycytidine kinase are related to CDA08 through their roles in these disorders linking drug resistance mechanisms with nucleotide metabolism.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com